Patent claims

1. Use of

5

- a) 8-cyanoquinolone antibiotics or
- b) quinolone antibiotics selected from the group consisting of: garenoxacin, marbofloxacin, ibafloxacin, danofloxacin, difloxacin and orbifloxacin

for preparing medicaments for the systemic treatment of bacterial infections of the oral cavity.

2. Use according to Claim 1 of 8-cyanoquinolone antibiotics of the formula (I):

$$F \xrightarrow{X} O COOR^2$$

$$Y \xrightarrow{A} N \xrightarrow{N} I$$

$$R^1$$
(I)

in which

- X represents hydrogen, halogen, C₁₋₄-alkyl, C₁₋₄-alkoxy, NH₂,
- Y represents radicals of the structure

in which

- R^4 represents optionally hydroxyl- or methoxy-substituted straight-chain or branched C_{1^-4} -alkyl, cyclopropyl, acyl having 1 to 3 carbon atoms,
- R⁵ represents hydrogen, methyl, phenyl, thienyl or pyridyl,
- R⁶ represents hydrogen or C₁₋₄-alkyl,
- R⁷ represents hydrogen or C_{1-4} -alkyl,

R⁸ represents hydrogen or C₁₋₄-alkyl,

and

- R¹ represents an alkyl radical having 1 to 3 carbon atoms, cyclopropyl, 2-fluoroethyl, methoxy, 4-fluorophenyl, 2,4-difluorophenyl or methylamino,
- R² represents hydrogen or optionally methoxy- or 2-methoxyethoxy-substituted alkyl having 1 to 6 carbon atoms and also cyclohexyl, benzyl, 2-oxopropyl, phenacyl, ethoxycarbonylmethyl, pivaloyloxymethyl,
 - A represents =C(CN),

and their pharmaceutically acceptable salts and hydrates.

- 10 3. Use according to Claim 1 where the 8-cyanoquinolone antibiotic is Pradofloxacin.
 - 4. Use according to Claim 1 for treating gingivitis, stomatitis, parodontitis and/or abscesses of the oral cavity.
- Use according to Claim 1 where the disorders are mainly caused by bacteria of the group consisting of Porphyromonas spp., Prevotella spp., Bacteroides spp., Actinobacillus actinomycetemcomitans, Fusobacterium spp., Peptostreptococcus spp., Eikenella corrodens, Capnocytophaga ochracea, Campylobacter rectus.